Search Medical Condition
Please enter condition
Please choose location

Johns Creek, Georgia Clinical Trials

A listing of Johns Creek, Georgia clinical trials actively recruiting patient volunteers.

RESULTS

Found (90) clinical trials

A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

The study consists of Screening Phase(4 weeks before administration of study drug),Active Treatment Phase(Week 0-Week 44),Follow Up Phase(Week 44-Week 56).During various study periods,safety assessments(example[e.g] recording of adverse events,Vital signs,Tuberculosis evaluation,Chest radiograph,Urine pregnancy Test);Efficacy assessments(e.g IGA,PASI);Clinical Laboratory Assessments(e.g haematology,chemistry);Biomarkers/Genetic evaluations,will be performed per the study procedures.The primary hypotheses are that guselkumab ...

Phase

2.5 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

This is a randomized, multicenter, double-blind, vehicle-controlled, 2 arm study to evaluate the safety and efficacy of FMX103 topical foam containing 1.5% minocycline compared to vehicle, in the treatment of subjects with moderate-to-severe facial papulopustular rosacea. Qualified subjects will be randomized to receive 1 of the following 2 treatments: - ...

Phase

2.5 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

The study will investigate the antidepressant effects of a range of doses of JNJ-42847922 (versus placebo), as adjunctive treatment to antidepressant drugs for treatment of MDD, and will assess the safety and tolerability of JNJ-42847922. The study will be conducted in 3 phases: a screening phase (up to 4 weeks), ...

Phase

2.5 miles

Learn More »

Evaluate the Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects (Ages 2 to 11 Years Inclusive) With Mild to Moderate Plaque Psoriasis.

This is a multicenter, open-label, Phase 1 study in a total of 75 pediatric subjects, ages 2 to 11 years, inclusive, with mild or moderate plaque psoriasis. The study will enroll sufficient subjects with plaque psoriasis and an ISGA score of mild to moderate (score of 2 or 3) at ...

Phase

2.5 miles

Learn More »

This Phase 3 study is intended to provide evidnece of the efficacy and safety of study drug when dosed twice a day in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of study drug in improving signs and symptoms and physical function that ...

Phase

2.5 miles

Learn More »

24-Week trial comparing treatment with Study Medicine vs. placebo. Patient Inclusion Criteria: Age >/= 18 Diagnosis of definite AS Active AS Inadequate response to treatment. Patient Exclusion Criteria: Major Surgery within 8 weeks prior to screening Inflammatory Disease other than AS Treatment with Investigational Medication within 4 weeks Hepatitis B, ...

Phase

2.5 miles

Learn More »

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Of Study Medicine On Peripheral Nerve Function In Patients With Osteoarthritis Patient Inclusion Criteria: BMI less or equal to 39 kg/m2 Osteoarthritis (arthritis) of the knee or hip with pain score that qualifies Patient Exclusion Criteria: Untreated, uncontrolled diseases, Unwilling or unable ...

Phase

2.5 miles

Learn More »

This study is designed to evaluate safety and assess initial efficacy of Study Medication, a JAK3 inhibitor, for treatment of subjects with active RA. This study will assess the clinical response of 4 doses of Study Medication compared to placebo when administered for 12 weeks to patients with active RA. ...

Phase

2.5 miles

Learn More »

A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Investigational Product in Patients With Systemic Lupus Erythematosus (SLE) Patient Inclusion Criteria: Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria Have positive antinuclear antibodies (ANA) Agree not to become pregnant ...

Phase

2.5 miles

Learn More »

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy Patient Inclusion Criteria: Diagnosis of Rheumatoid Arthritis (RA) of more than 6 months and less than 15 years ...

Phase

2.5 miles

Learn More »